RyanHanrahanNov2017HARTFORD: Guilford’s, Ryan Hanrahan has been appointed NBC Connecticut / WVIT First Alert Weather team’s new Chief Meteorologist. Ryan will deliver “real-time” weather forecasts for the station’s weekday evening newscasts from 4 p.m. to 6:30 p.m. and at 11 p.m.

Susan Tully, President and General Manager of NBC Connecticut, in announcing the promotion said. “Ryan delivers accurate, no-nonsense forecasts. I am confident he will thrive in this new role,” said. “His expertise and Connecticut roots blend to provide an unmatched knowledge that our viewers can trust.”

“Becoming a Chief Meteorologist in Connecticut has been a dream of mine since I was a kid growing up on the shoreline,” added Hanrahan. “I’m thrilled for this opportunity and excited to continue to share my love of weather and science with our viewers and in my home state.”

According to the station Hanrahan’s interest in weather was “sparked by the 1989 tornado in Hamden, as well as hurricanes Gloria and Bob. “

Ryan has a degree in Meteorology from Pennsylvania State University, at the NBC affiliate in Albany, New York, WNYT. Hanrahan first joined NBC Connecticut in 2005, after studying atmospheric science in graduate school at SUNY Albany. In 2016, he was awarded a New England Regional Emmy in the “Weather Anchor” category in recognition of his weather forecasts and coverage.

naderNEW HAVEN: Alexion Pharmaceuticals, Inc. [NASDAQ: ALXN] is adding some bioscience chops to its board appointing Francois Nader, M.D.

The company says “Nader is an accomplished leader in the biopharmaceutical industry with a proven track record of building and transforming companies, launching rare disease therapies, and creating significant shareholder value.”

Just last week in an editorial recognizing the gaps in Alexion’s board, Business New Haven, Conntact.com called for an expansion of bioscience experience on the board, as the company seeks to create a new drug pipeline, dependent on licensing and or acquisitions.

New Haven: Three executives from pharma giant Bristol Myers Squibb [NYSE: BMY] are finding new homes at two affiliated New Haven biotech companies. Biohaven [NYSE: BHVN] which went public two months ago with a $168 million IPO has hired two former BMY execs for key leadership positions as the company continues to move forward on developing its diverse portfolio of drugs.

manion
Manion: new CEO at KLEO
stock
Stock:  appointed head of Portfolio Strategy and Development at Biohaven
mcgrath
McGrath: Chief of Corporate Strategy and Business Development, Biohaven.

Elyse Stock, M.D. has been appointed as the company's Chief of Portfolio Strategy and Development, and St. John (Donnie) McGrath, M.D. has been appointed as Chief of Corporate Strategy and Business Development.

Douglas Manion, M.D., FRCP(C), as the new CEO of Kleo Pharmaceuticals. Manion has most recently served as SVP head of specialty development at BMS. Kleo's lead investor is Biohaven.

David Spiegel, M.D., Ph.D. co-founder of Kleo who’s technology is based on the work of his lab at Yale University, was himself appointed CEO this past September soon after the  investment led by Biohaven.

Stock was most Vice-President Global Development Leader at Bristol-Myers Squibb (BMS), where she worked for the last 19 years in various positions “developing numerous investigational agents across multiple therapeutic areas including neuroscience, oncology, immunology and cardiovascular disease.”

McGrath, served as Vice President of Business Development and Head of Search & Evaluation. was responsible for overseeing BMS' venture capital investment portfolio and provided leadership for all global external partnering activities.

immeltBoston:  General Electric's [ NYSE: GE] CEO  Jeff Immelt is stepping down after seventeen years, John Flannery the president and CEO of GE Healthcare, has been named chairman and CEO

Immelt will remain chairman of the board through his retirement from the company on December 31, 2017. Immelt is 61 and GE’s mandatory retirement age is 65.

In 2015 Immelt announced a move of GE’s suburban Fairfield headquarters to Boston. The majority of GE’s employees however did stay in Connecticut, moving more than 600 employees to Norwalk. GE’s Fairfield suburban campus valued by some at more than $75 million was sold to Sacred Heart University for only $35 million. The GE campus is nearly continguous to the Sacred Heart campus. Scared Heart and GE have had a long standing relationship and former CEO Jack Welch donated heavily to the school and it hosts the Jack Welch College of Business.

Dittirich Chris SLAM Neff Rod SLAM
Dittirich Neff

Glastonbury: S/L/A/M Construction Services (SLAM CS) has hired Rod Neff, CHFM, and Chris Dittrich, CDT, as senior project managers.

Neff, a Certified Healthcare Facility Manager (CHFM), brings 30 years of construction industry experience to SLAM CS, including 20 years in the healthcare industry. In his previous position, Neff was the senior project manager for many healthcare projects in Connecticut and Mass.

Dittrich has 13 years of experience working in the construction industry, seven of which have included working for SLAM CS as a project manager and cost estimator.  Dittrich has completed more than 24 new construction and renovation projects in the healthcare, corporate, educational, residential and public markets.

orloff
 John Orloff, New Alexion R&D Head did seven Years at Yale Med School

By Mitchell Young

Key Executive Hires From Hantson's Previous Company, Baxalta

New Haven: What new Alexion [ Nasdaq{: ALXN ]CEO  Ludwig Hantson has in mind in his C Suite makeover has gotten a little more clear. In Early May, the company announced the departure of four key executives, including Martin Mackay, EVP and the head of R&D for the company who will “retire” this year. McKay joined Alexion in 2013 and will be replaced by John Orloff, M.D.

Orloff has most recently been head of R&D at Novelion [Nasdaq: NVLN] a small $175 million market cap rare disease biotech headquartered in Vancouver, B.C. with operations in Cambridge Mass as well.

Before then, Orloff was global head of R&D and CSO [Chief Science Officer] at Baxalta, where he worked for then CEO Hantson.